{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T17:40:42Z","timestamp":1773769242599,"version":"3.50.1"},"reference-count":39,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,2]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Peginterferon (PegIFN) has shown promising results in the treatment of chronic hepatitis B (CHB). This study aimed to evaluate the effects of PegIFN \u03b1-2b on growth and thyroid function in young children with CHB.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>A retrospective study was performed by extracting clinical data from children with CHB who received PegIFN \u03b1-2b monotherapy at the Public Health Clinical Center of Chengdu between June 2017 and December 2020. Mean, SD, independent samples <jats:italic toggle=\"yes\">t<\/jats:italic> test and 1-way repeated analysis of variance were used to evaluate relevant data.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>A total of 62 children were included in this study. Overall, significant differences were observed in the weight-for-age z score (WAZ), height-for-age z score (HAZ) and body mass index-for-age z score (BAZ) at different time points (<jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.001). WAZ, HAZ and BAZ were not affected by PegIFN \u03b1-2b at 24 weeks of treatment (all <jats:italic toggle=\"yes\">P<\/jats:italic> &gt; 0.05). WAZ, HAZ and BAZ at the end of treatment and 48 weeks after treatment; WAZ at 96 weeks after treatment were lower than baseline levels (all <jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.05). No statistical differences were found in HAZ and BAZ at 96 weeks after treatment compared with baseline. Thyroid dysfunction developed in 17.7% of children during the treatment. Thyroid dysfunction was transient and had no effect on growth.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>PegIFN \u03b1-2b has inhibitory effects on growth and can increase the incidence of thyroid dysfunction in young children with CHB. These effects are generally reversible with the cessation of therapy, although WAZ had not returned to baseline after 96 weeks of observation.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/inf.0000000000004567","type":"journal-article","created":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T15:04:39Z","timestamp":1727708679000},"page":"112-117","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Dynamic Changes of Growth and Thyroid Function in Young Children With Chronic Hepatitis B Treated With Peginterferon Monotherapy"],"prefix":"10.1097","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1286-694X","authenticated-orcid":false,"given":"Qiufeng","family":"He","sequence":"first","affiliation":[{"name":"Department of Hepatology, Public Health Clinical Center of Chengdu, Chengdu, Sichuan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3170-4361","authenticated-orcid":false,"given":"Chuangjie","family":"Mao","sequence":"additional","affiliation":[{"name":"Department of Hepatology, Public Health Clinical Center of Chengdu, Chengdu, Sichuan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhili","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Hepatology, Public Health Clinical Center of Chengdu, Chengdu, Sichuan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2934-4910","authenticated-orcid":false,"given":"Fangfang","family":"Duan","sequence":"additional","affiliation":[{"name":"Department of Hepatology, Beijing Ditan Hospital, Capital Medical University, Beijing, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liang","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Hepatology, Public Health Clinical Center of Chengdu, Chengdu, Sichuan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1051-5182","authenticated-orcid":false,"given":"Rong","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Hepatology, Public Health Clinical Center of Chengdu, Chengdu, Sichuan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Deng","sequence":"additional","affiliation":[{"name":"Department of Hepatology, Public Health Clinical Center of Chengdu, Chengdu, Sichuan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5579-8353","authenticated-orcid":false,"given":"Jun","family":"Cheng","sequence":"additional","affiliation":[{"name":"Department of Hepatology, Beijing Ditan Hospital, Capital Medical University, Beijing, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6046-5756","authenticated-orcid":false,"given":"Song","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Hepatology, Beijing Ditan Hospital, Capital Medical University, Beijing, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5777-5702","authenticated-orcid":false,"given":"Yilan","family":"Zeng","sequence":"additional","affiliation":[{"name":"Department of Hepatology, Public Health Clinical Center of Chengdu, Chengdu, Sichuan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2024,10,1]]},"reference":[{"key":"R1-20250721","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1093\/jnci\/92.14.1159","article-title":"Familial risk of hepatocellular carcinoma among chronic hepatitis B carriers and their relatives.","volume":"92","author":"Yu","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"R2-20250721","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.4254\/wjh.v7.i8.1064","article-title":"Risk for hepatocellular carcinoma in the course of chronic hepatitis B virus infection and the protective effect of therapy with nucleos(t)ide analogues.","volume":"7","author":"Rapti","year":"2015","journal-title":"World J Hepatol"},{"key":"R3-20250721","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1080\/17474124.2019.1686975","article-title":"Updates in the management of hepatitis B in children.","volume":"13","author":"Lai","year":"2019","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"R4-20250721","first-page":"59","article-title":"The management of hepatitis B and hepatitis C in children.","volume":"71","author":"Batsis","year":"2019","journal-title":"Minerva Pediatr"},{"key":"R5-20250721","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/j.jhep.2013.05.016","article-title":"Management of chronic hepatitis B in childhood: ESPGHAN clinical practice guidelines: consensus of an expert panel on behalf of the European Society of Pediatric Gastroenterology, Hepatology and Nutrition.","volume":"59","author":"Sokal","year":"2013","journal-title":"J Hepatol"},{"key":"R6-20250721","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection.","volume":"67","year":"2017","journal-title":"J Hepatol"},{"key":"R7-20250721","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance.","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"key":"R8-20250721","first-page":"1425","article-title":"Guidelines for the prevention and treatment of chronic hepatitis B (version 2022).","volume":"11","author":"You","year":"2023","journal-title":"J Clin Transl Hepatol"},{"key":"R9-20250721","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1159\/000484258","article-title":"Interferon-stimulated genes as enhancers of antiviral innate immune signaling.","volume":"10","author":"Crosse","year":"2018","journal-title":"J Innate Immun"},{"key":"R10-20250721","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1136\/gut.46.5.715","article-title":"Long term effect of alpha interferon in children with chronic hepatitis B.","volume":"46","author":"Bortolotti","year":"2000","journal-title":"Gut"},{"key":"R11-20250721","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1097\/INF.0000000000002876","article-title":"Efficacy and safety of pegylated interferon for the treatment of chronic hepatitis B in children and adolescents: a systematic review and meta-analysis.","volume":"39","author":"He","year":"2020","journal-title":"Pediatr Infect Dis J"},{"key":"R12-20250721","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/j.jhep.2021.11.024","article-title":"How to achieve functional cure of HBV: stopping NUCs, adding interferon or new drug development?","volume":"76","author":"Wong","year":"2022","journal-title":"J Hepatol"},{"key":"R13-20250721","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1111\/hepr.12118","article-title":"Effects of pegylated interferon-\u03b1-2a monotherapy on growth in Japanese children with chronic hepatitis C.","volume":"44","author":"Tsunoda","year":"2014","journal-title":"Hepatol Res"},{"key":"R14-20250721","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1002\/hep.25690","article-title":"Pegylated interferon for chronic hepatitis C in children affects growth and body composition: results from the pediatric study of hepatitis C (PEDS-C) trial.","volume":"56","author":"Jonas","year":"2012","journal-title":"Hepatology"},{"key":"R15-20250721","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/MPG.0000000000001239","article-title":"Long-term follow-up of children treated with peginterferon and ribavirin for hepatitis C virus infection.","volume":"64","author":"Haber","year":"2017","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"R16-20250721","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1089\/jir.2016.0007","article-title":"Thyroid dysfunction in chronic hepatitis C patients treated with the combined pegylated interferon-ribavirin therapy.","volume":"36","author":"Hamza","year":"2016","journal-title":"J Interferon Cytokine Res"},{"key":"R17-20250721","first-page":"555","article-title":"Long-term outcomes of thyroid dysfunction in patients with chroni\u0107 hepatitis C treated with pegylated interferon alpha and ribavirin.","volume":"71","author":"Kozielewicz","year":"2017","journal-title":"Przegl Epidemiol"},{"key":"R18-20250721","doi-asserted-by":"crossref","first-page":"792","DOI":"10.3904\/kjim.2015.30.6.792","article-title":"Incidence of and risk factors for thyroid dysfunction during peginterferon \u03b1 and ribavirin treatment in patients with chronic hepatitis C.","volume":"30","author":"Hwang","year":"2015","journal-title":"Korean J Intern Med"},{"key":"R19-20250721","doi-asserted-by":"crossref","first-page":"e003735","DOI":"10.1136\/bmjopen-2013-003735","article-title":"Worldwide variation in human growth and the World Health Organization growth standards: a systematic review.","volume":"4","author":"Natale","year":"2014","journal-title":"BMJ Open"},{"key":"R20-20250721","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1017\/S136898001200105X","article-title":"Worldwide implementation of the WHO Child Growth Standards.","volume":"15","author":"de Onis","year":"2012","journal-title":"Public Health Nutr"},{"key":"R21-20250721","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1002\/hep.30050","article-title":"Efficacy and safety of peginterferon alfa-2a (40KD) in children with chronic hepatitis B: the PEG-B-ACTIVE study.","volume":"68","author":"Wirth","year":"2018","journal-title":"Hepatology"},{"key":"R22-20250721","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1002\/hep.30312","article-title":"Combination of entecavir\/peginterferon alfa-2a in children with hepatitis B e antigen-positive immune tolerant chronic hepatitis B virus infection.","volume":"69","author":"Rosenthal","year":"2019","journal-title":"Hepatology"},{"key":"R23-20250721","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s12519-019-00303-w","article-title":"Efficacy and safety of interferon alpha-2b versus pegylated interferon alpha-2a monotherapy in children with chronic hepatitis B: a real-life cohort study from Shanghai, China.","volume":"15","author":"Hu","year":"2019","journal-title":"World J Pediatr"},{"key":"R24-20250721","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1111\/j.1365-2036.2004.02170.x","article-title":"Review article: pegylated interferons: chemical and clinical differences.","volume":"20","author":"Foster","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"key":"R25-20250721","doi-asserted-by":"crossref","first-page":"2724","DOI":"10.1111\/j.1572-0241.2007.01445.x","article-title":"Hepatitis-C patients have reduced growth hormone (GH) secretion which improves during long-term therapy with pegylated interferon-alpha.","volume":"102","author":"Pl\u00f6ckinger","year":"2007","journal-title":"Am J Gastroenterol"},{"key":"R26-20250721","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1515\/JPEM.2007.20.5.615","article-title":"The influence of interferon-alpha and combination interferon-alpha and lamivudine therapy on height and weight in children with chronic hepatitis B infection.","volume":"20","author":"Kulo\u011flu","year":"2007","journal-title":"J Pediatr Endocrinol Metab"},{"key":"R27-20250721","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1007\/BF02532525","article-title":"Influence of recombinant interferon alpha on nutritional status and growth pattern in children with chronic viral hepatitis.","volume":"155","author":"Gottrand","year":"1996","journal-title":"Eur J Pediatr"},{"key":"R28-20250721","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1016\/j.jpeds.2014.08.010","article-title":"Long-term growth outcomes in children treated for chronic hepatitis C.","volume":"165","author":"Jonas","year":"2014","journal-title":"J Pediatr"},{"key":"R29-20250721","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.mce.2017.01.025","article-title":"The classic pathways of thyroid hormone metabolism.","volume":"458","author":"van der Spek","year":"2017","journal-title":"Mol Cell Endocrinol"},{"key":"R30-20250721","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1080\/08916934.2016.1191475","article-title":"Association of established thyroid peroxidase autoantibody (TPOAb) genetic variants with Hashimoto\u2019s thyroiditis.","volume":"49","author":"Br\u010di\u0107","year":"2016","journal-title":"Autoimmunity"},{"key":"R31-20250721","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.autrev.2004.03.003","article-title":"Interferon induced autoimmune thyroid disease (AITD): a model for human autoimmunity.","volume":"3","author":"Oppenheim","year":"2004","journal-title":"Autoimmun Rev"},{"key":"R32-20250721","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.ghir.2014.04.004","article-title":"Effects of levothyroxine on growth hormone (gh) sensitivity in children with idiopathic short stature.","volume":"24","author":"Garc\u00eda","year":"2014","journal-title":"Growth Horm IGF Res"},{"key":"R33-20250721","doi-asserted-by":"crossref","first-page":"51","DOI":"10.4274\/jcrpe.v3i2.11","article-title":"Thyroid hormones and growth in health and disease.","volume":"3","author":"Tarim","year":"2011","journal-title":"J Clin Res Pediatr Endocrinol"},{"key":"R34-20250721","doi-asserted-by":"crossref","first-page":"245","DOI":"10.4103\/2229-516X.192587","article-title":"Prevalence of thyroid disorders in hepatitis C virus positive patients on interferon and antiviral therapy.","volume":"6","author":"Goyal","year":"2016","journal-title":"Int J Appl Basic Med Res"},{"key":"R35-20250721","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1097\/INF.0000000000001791","article-title":"Transient hypothyroidism and autoimmune thyroiditis in children with chronic hepatitis C treated with pegylated-interferon-\u03b1-2b and ribavirin.","volume":"37","author":"Serranti","year":"2018","journal-title":"Pediatr Infect Dis J"},{"key":"R36-20250721","doi-asserted-by":"crossref","first-page":"52","DOI":"10.3345\/kjp.2018.07150","article-title":"Thyroid disturbances in children treated with combined pegylated interferon-alpha and ribavirin for chronic hepatitis C.","volume":"63","author":"Rashed","year":"2020","journal-title":"Clin Exp Pediatr"},{"key":"R37-20250721","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1111\/jvh.13667","article-title":"Thyroid dysfunction incidence and risk factors in Chinese chronic hepatitis B patients treated with pegylated interferon alpha: A long-term follow-up study.","volume":"29","author":"Ma","year":"2022","journal-title":"J Viral Hepat"},{"key":"R38-20250721","doi-asserted-by":"crossref","first-page":"3020","DOI":"10.1128\/AAC.00088-07","article-title":"Pegylated interferon Alfa-2b monotherapy and pegylated interferon Alfa-2b plus lamivudine combination therapy for patients with hepatitis B virus E antigen-negative chronic hepatitis B.","volume":"51","author":"Kaymakoglu","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"R39-20250721","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1517\/14740338.2014.921156","article-title":"Can pegylated interferon \u03b1 2a cause development of thyroid disorders in patients with chronic hepatitis B?","volume":"13","author":"Kozielewicz","year":"2014","journal-title":"Expert Opin Drug Saf"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000004567","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T19:00:27Z","timestamp":1753124427000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000004567"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,1]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000004567","relation":{},"ISSN":["0891-3668","1532-0987"],"issn-type":[{"value":"0891-3668","type":"print"},{"value":"1532-0987","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,1]]}}}